Core Insights - CERo Therapeutics Holdings, Inc. is presenting a poster at the ASCO 2025 Annual Meeting, showcasing its innovative approach to engineered T cell therapeutics targeting cancer [1][2] - The poster details a first-in-human study of CER-1236, an autologous chimeric engulfment receptor T-cell therapy aimed at treating acute myeloid leukemia [2] - The study is a multi-center, open-label, Phase 1/1b trial focusing on safety and preliminary efficacy, with primary outcome measures including adverse events and overall response rates [2] Company Overview - CERo is focused on developing next-generation engineered T-cell therapeutics that integrate characteristics of both innate and adaptive immunity [3] - The company’s proprietary technology aims to redirect patient-derived T cells to eliminate tumors through phagocytic mechanisms, creating Chimeric Engulfment Receptor T cells (CER-T) [3] - CERo believes that CER-T cells will have broader therapeutic applications compared to current CAR-T therapies, potentially addressing both hematological malignancies and solid tumors [3]
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting